Assays for measuring nucleic acids
US-2024226890-A1 · Jul 11, 2024 · US
Methods for determining resistance or susceptibility to HIV entry inhibitors
US9506121B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9506121-B2 |
| Application number | US-92175106-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 6, 2006 |
| Priority date | Jun 6, 2005 |
| Publication date | Nov 29, 2016 |
| Grant date | Nov 29, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides a method for determining whether a human immunodeficiency virus is likely to be more resistant to a viral entry inhibitor than a reference HIV. In certain aspects, the methods comprise comparing the length of one or more variable regions of an envelope protein of the HIV or a number of glycosylation sites on the envelope protein of the HIV to a length of one or more corresponding variable regions of an envelope protein of the reference HIV or a number of glycosylation sites on the envelope protein of the reference HIV, wherein the HIV is likely to be more resistant to the CD4 binding site entry inhibitor than the reference HIV when the HIV has longer variable regions than the reference HIV or the HIV has more glycosylation sites than the reference HIV.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for selecting a treatment for a patient having a human immunodeficiency virus (HIV) infection, comprising: a) determining a length of one or more variable regions of an envelope protein of an HIV from the patient or a number of glycosylation sites on the envelope protein of the HIV; b) comparing the length of the one or more variable regions of the envelope protein of the HIV or the number of glycosylation sites on the envelope protein of the HIV…
Assignees
Inventors
Classifications
- C12Q1/703Primary
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9506121B2 cover?
- The invention provides a method for determining whether a human immunodeficiency virus is likely to be more resistant to a viral entry inhibitor than a reference HIV. In certain aspects, the methods comprise comparing the length of one or more variable regions of an envelope protein of the HIV or a number of glycosylation sites on the envelope protein of the HIV to a length of one or more corre…
- Who is the assignee on this patent?
- Huang Wei, Monogram Biosciences Inc
- What technology area does this patent fall under?
- Primary CPC classification C12Q1/703. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Nov 29 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).